Takeda Pharmaceutical's United Kingdom subsidiary has begun working with C4X Discovery to improve its lead discovery and hit identification. The agreement is centered on C4XD's 3D drug technology, a nuclear magnetic resonance-based method of viewing the structure of a molecule.
IBM has opened up its Watson supercomputer to drug researchers through a new cloud-based service. And Big Pharma companies are already on board, with Johnson & Johnson and Sanofi among the early adopters of the technology.
With its big claims about how artificial intelligence can slash drug development timelines and a lead candidate based on a coenzyme best known as a dietary supplement, Berg is always likely to provoke skepticism. But the company is sticking to its guns, with President and CTO Niven Narain pointing to early drug discovery successes as evidence of its legitimacy.
The challenge calls on competitors to create the most accurate algorithms for detecting Single Nucleotide Variants (SNVs) and Structural Variations (SVs).
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
Although Numenta has made progress in creating apps that reproduce the brain, it thinks a fully functioning model is impossible without rethinking the underlying hardware.
Two hundred eighty scientists have signed an open letter threatening to boycott Europe's Human Brain Project. The scientists have fundamental concerns about exactly what Europe is trying to achieve with its €1 billion ($1.4 billion) budget.
Evangelists of 3-D printing tip the technology to reshape organ transplants, orthopedics and multiple other areas of medicines, with Johnson & Johnson among the companies trying to turn hype into reality. And now the National Institutes of Health has joined the sector, adding a 3-D model creation service to help drug researchers who lack computing skills.
X-Chem has notched up some notable achievements in its first few years, including investment by CRO PPD, deals with AstraZeneca and Roche and the growth of its compound library to 100 billion small molecules. Now it has added another to the list by striking a drug discovery deal with Pfizer.
The emergence of electronic health records has made it possible to build a more complete picture of the health of populations. To realize this vision for diabetes patients, AstraZeneca has signed up to sponsor a registry that gathers data from primary care physicians and specialists in other fields.